Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2
- 30 November 2006
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 136 (2) , 343-344
- https://doi.org/10.1111/j.1365-2141.2006.06409.x
Abstract
Acute pulmonary injury is known as acute chest syndrome (ACS) in patients with sickle cell disease (SCD). Secretory phospholipase A2 (sPLA2) was found to predict those at risk for ACS and a trial was designed to determine if red blood cell transfusion can be used to prevent ACS. Patients with an elevated sPLA2 were randomised to either receive a single transfusion or standard care. Five of the eight patients (63%) randomised to standard care developed ACS versus none of the seven patients randomised to the transfusion arm (P = 0.026, Odds ratio = 23.6, 95% confidence interval 1, 557). This study suggests that transfusion may prevent ACS.Keywords
This publication has 7 references indexed in Scilit:
- Serum Biomarkers for Identifying Acute Chest Syndrome Among Patients Who Have Sickle Cell Disease and Present to the Emergency DepartmentPublished by American Academy of Pediatrics (AAP) ,2005
- Secretory phospholipase A2 activity correlates with postinjury multiple organ failureCritical Care Medicine, 2001
- Secretory phospholipase A2 predicts impending acute chest syndrome in sickle cell diseaseBlood, 2000
- Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell DiseaseNew England Journal of Medicine, 2000
- Acute Chest Syndrome in Sickle Cell Disease: Clinical Presentation and CourseBlood, 1997
- Phospholipase A2 levels in acute chest syndrome of sickle cell diseaseBlood, 1996